Study S001134

A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of JY09 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06257966
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 600
Start: 2024-07-17
Primary completion: 2026-10-01
Lead sponsor: Beijing Dongfang Biotech Co., Ltd.
Conditions: Type2 Diabetes Mellitus
Interventions: DRUG:Exendin-4 Fc fusion protein injection(1.2mg）; DRUG:Exendin-4 Fc fusion protein injection（2.4mg）; DRUG:Dulaglutide; DRUG:Metformin
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

HbA1c [Baseline, Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.